CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus
- PMID: 19729087
- DOI: 10.1016/j.vaccine.2009.08.047
CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus
Abstract
Poliovirus transmission is controlled globally through world-wide use of a live attenuated oral polio vaccine (OPV). However, the imminence of global poliovirus eradication calls for a switch to the inactivated polio vaccine (IPV). Given the limited manufacturing capacity and high cost of IPV, this switch is unlikely in most developing and undeveloped countries. Adjuvantation is an effective strategy for antigen sparing. In this study, we evaluated the adjuvanticity of CpG oligodeoxynucleotides (CpG-ODN) for an experimental IPV produced from Sabin strains of poliovirus. Our results showed that CpG-ODN, alone or in combination with alum, can significantly enhance both the humoral and cellular immune responses to IPV in mice, and, consequently, the antigen dose could be reduced substantially. Therefore, our study suggests that the global use of IPV could be facilitated by using CpG-ODN or other feasible adjuvants.
Similar articles
-
Analysis of the dose-sparing effect of adjuvanted Sabin-inactivated poliovirus vaccine (sIPV).Hum Vaccin Immunother. 2018;14(8):1987-1994. doi: 10.1080/21645515.2018.1454571. Epub 2018 May 10. Hum Vaccin Immunother. 2018. PMID: 29601259 Free PMC article.
-
Anomalous observations on IPV and OPV vaccination.Dev Biol (Basel). 2001;105:197-208. Dev Biol (Basel). 2001. PMID: 11763328
-
Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants.J Infect Dis. 2007 Sep 1;196(5):692-8. doi: 10.1086/520546. Epub 2007 Jul 23. J Infect Dis. 2007. PMID: 17674310 Clinical Trial.
-
Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains.Expert Rev Vaccines. 2011 May;10(5):635-44. doi: 10.1586/erv.11.51. Expert Rev Vaccines. 2011. PMID: 21604984 Review.
-
World wide experience with inactivated poliovirus vaccine.Vaccine. 2008 Sep 15;26(39):4978-83. doi: 10.1016/j.vaccine.2008.07.026. Epub 2008 Aug 3. Vaccine. 2008. PMID: 18680777 Review.
Cited by
-
Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication.Hum Vaccin Immunother. 2022 Dec 30;18(7):2154100. doi: 10.1080/21645515.2022.2154100. Epub 2022 Dec 28. Hum Vaccin Immunother. 2022. PMID: 36576132 Free PMC article. Review.
-
Advax-CpG Adjuvant Provides Antigen Dose-Sparing and Enhanced Immunogenicity for Inactivated Poliomyelitis Virus Vaccines.Pathogens. 2021 Apr 21;10(5):500. doi: 10.3390/pathogens10050500. Pathogens. 2021. PMID: 33919442 Free PMC article.
-
Determination of Depth-Dependent Intradermal Immunogenicity of Adjuvanted Inactivated Polio Vaccine Delivered by Microinjections via Hollow Microneedles.Pharm Res. 2016 Sep;33(9):2269-79. doi: 10.1007/s11095-016-1965-6. Epub 2016 Jun 17. Pharm Res. 2016. PMID: 27317570
-
Generation of human MHC (HLA-A11/DR1) transgenic mice for vaccine evaluation.Hum Vaccin Immunother. 2016 Mar 3;12(3):829-36. doi: 10.1080/21645515.2015.1103405. Hum Vaccin Immunother. 2016. PMID: 26479036 Free PMC article.
-
Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01.PLoS One. 2014 Jun 23;9(6):e100879. doi: 10.1371/journal.pone.0100879. eCollection 2014. PLoS One. 2014. PMID: 24956110 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical